ORGANIZATION OF AMERICAN STATES



INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION



FORTY-FIFTH REGULAR SESSION May 6 - 8, 2009 Washington, DC OEA/Ser.L/XIV.2.45 CICAD/doc.1733/09 5 May 2009 Original: English

DR. STEVEN G. TOSKE SPECIAL TESTING AND RESEARCH LABORATORY

U.S. DEPARTMENT OF JUSTICE

DRUG ENFORCEMENT ADMINISTRATION (DEA)

Extraction of Methamphetamine Precursor Material from Medicinal Preparations and Methamphetamine Profiling Results




Dr. Steven G. Toske Special Testing and Research Laboratory

Common Methamphetamine Precursors

- Ephedrine or Pseudoephedrine
- Phenyl-2-Propanone (P2P)

Pseudoephedrine/Ephedrine (Sources)

- Ephedrine/Pseudoephedrine are natural products that can be isolated individually from the Ephedra plant commonly cultivated in China and India.
- Ephedra products can be obtained in tablet or capsule form as part of diet pills..





Pseudoephedrine/Ephedrine (Sources)

- Pseudoephedrine HCl and Ephedrine HCl can be produced synthetically
- Ephedrine HCl is used as a stimulant/decongestant to control asthma
- Pseudoephedrine HCl is a common ingredient in Over-the-Counter decongestant tablets





Simple Extraction of Tablets







- Grind Tablets
- Alcohol
- Filter
- Evaporate
- Resulting Powder Contains Pseudoephedrine or Ephedrine






Cold and Flu Preparations Containing Pseudoephedrine Hydrochloride



Cold and Flu Preparations Containing Pseudoephedrine Hydrochloride


| Product | Form | Pseudoephedrine HCl per dose (mg) | Co-Ingredients |
|---------|--------------------------|--------------------------------------|--|
| 1 | tablets | 30 | acetaminophen (500 mg) |
| 2 | coated tablets | 30 | acetaminophen (500 mg) diphenhydramine HCl (25 mg) |
| 3 | soft gelatin capsules | 30 | acetaminophen (250 mg) dextromethorphan HBr (10mg) guaifenesin (100 mg) |
| 4 | soft gelatin capsules | 30 | acetaminophen (325 mg) dextromethorphan HBr (15 mg) |
| 5 | liquid | 30 (15 mL) | acetaminophen (500 mg) dextromethorphan HBr (15 mg) doxylamine succinate (7.25 mg) |

Acid/Base Tablet Extraction




Grind Tablets
Coated Tablet Powder Pass

Coated Tablet Powder Passed through Sieve to Remove Large Pieces of Coating



Adjust pH to 1 with HCl (Muriatic Acid Can Be Used)



Add Powder into Hot Water and Stir



Extract 3 Times with Ether (Starter Fluid Can Be Used)

Acid/Base Tablet Extraction



Discard Ether Washes



Extract 3 Times with Ether



Adjust pH to 12 with NaOH (Common Drain Cleaner Can Be Used)



Collect Ether Containing Pseudoephedrine

Acid/Base Tablet Extraction



Wash Ether with Water then Dry Using Sodium Sulfate



Pour or Filter Ether to Another Beaker for Evaporation



Final Pseudoephedrine Powder

Cold and Flu Preparations Extraction Results

| Product | Form | Purity of Recovered Pseudoephedrine Base (%) | Yield* (%) | Other Drugs Still Present |
|---------|--------------------------|--|------------|----------------------------------|
| 1 | tablets | 99 | 58 | None |
| 2 | coated tablets | 46 | 40 | acetaminophen diphenhydramine |
| 3 | soft gelatin capsules | 51 | 45 | dextromethorphan guaifenesin |
| 4 | soft gelatin capsules | 90 | 46 | dextromethorphan |
| 5 | liquid | 66 | 75 | dextromethorphan doxylamine |

^{*}Percentage of Pseudoephedrine Recovered, Calculated as Pseudoephedrine HCI

Allergy and Decongestant Preparations Containing Pseudoephedrine

| Product | Form | Pseudoephedrine per dose (mg) | Additional Drugs Present |
|--------------------------------|---------|----------------------------------|-----------------------------|
| 6 12 Hour Release | tablets | 120* | loratadine (5mg) |
| 7 24 Hour Release | tablets | 240* | loratadine (10mg) |
| 8 Extended Release | tablets | 60** | guaifenesin (600mg) |

^{*}Pseudoephedrine Sulfate

^{**}Pseudoephedrine HCl

Extraction Results

| Product | Extraction Procedure | Dosage Units Used | Purity of Recovered Pseudoephedrine Base (%) | Yield (%) |
|--------------------|-------------------------|----------------------|--|--------------|
| 6 (12 hour) | 1 | 20 | 95 | 60 |
| 6 | 1 | 10 | 96 | 62 |
| 7 (24 hour) | 1 | 20 | 43 | 3 |
| 7 | 2 | 10 | 25 | 8 |
| 7 | 3 | 5 | 70 | 38 |
| 7 | 4 | 5 | 46 | 10 |
| 7 | 5 | 10 | 66 | 26 |
| 7 | 6 | 10 | 89 | 22 |
| 7 | 7 | 10 | 71 | 9 |

Loratadine was present in all pseudoephedrine extracts

Product 8 Extraction Results

| Dosage Units Used (800 mg) | Purity of Recovered Pseudoephedrine Base (%) | Theoretical Weight Pseudoephedrine Base (mg) | Amount Pseudoephedrine Recovered (mg) (as base) | Yield (%) |
|-------------------------------------|--|--|--|--------------|
| 4 | 41* | 196.5 | 98.3 | 50** |

^{*}Extract also contained 56% guaifenesin.

^{**}Best Result after Several Poor Yielding Attempts
Using Procedure 1.

Extraction Conclusions

- In all cases, pseudoephedrine was extracted out with varying degrees of success (3% to 75% yields).
- The selected acid/base extraction worked well on the pseudoephedrine/acetaminophen tablets. Also, extraction of the 12h time release tablets was efficient.
- Lower pseudoephedrine purities were observed when other active drugs were present.
- The selected extraction methods used are not amenable for scaling up for the extended release formulations. However, there are other extraction methods available on the internet which may be effective.

Methamphetamine Profiling Program

- Selected samples from the seven U.S. regions are supplied by seven DEA regional labs.
- Samples representing the Mexico and Canada regions are obtained from border or Port-of-Entry seizures.
- Foreign samples have been obtained mainly from support to other governments.
- Since 4Q-2004: Purity, Isomer, Cutting Agent, OTC Impurity, and Synthetic Route Trends have been established and monitored.

MPP Regions



4Q-2008 Purity Trends (162 Samples)

| MPP Region | Overall Purity | Small Seizures | Medium Seizures | Large Seizures |
|-----------------------|----------------|-------------------|--------------------|-------------------|
| Northwest | 63.6 | 46.3 | 73.5 | 88.1* |
| Southwest | 76.5 | 66.7 | 71.8 | 91.4 |
| North Central | 51.2 | 44.1 | 59.0* | 100* |
| South Central | 52.2 | 44.9 | 35.3 | 80.1 |
| Northeast | 73.0 | 68.1 | NA | 79.6 |
| Southeast | 50.4 | 47.0 | 49.9 | 82.3 |
| Pacific | 97.0 | 96.7* | 97.2* | NA |
| Mexico | 97.0 | 99.1* | 94.7 | 97.4 |
| Canada | NA | NA | NA | NA |
| Foreign | 97.5 | 97.5* | NA | NA |
| Average Purity | 71.4 | 54.7 | 68.2 | 92.7 |


Small Seizure: 6 g to 100g

Medium Seizure: 101 g to 999 g

Large Seizure: > 1000 g

^{*} Only one sample was available in this category for the purity calculation.


d-Isomer Trend Line




Percentage of Antihistamine Drugs Detected as Trace Components 4Q-2008 (162 Samples)

| Chlorpheniramine | 46% |
|-------------------------------|-----|
| Triprolidine | 35% |
| Loratadine | 17% |
| Brompheniramine | 10% |
| Dextromethorphan | 5% |
| Carbinoxamine | 1% |
| Triprolidine/Chlorpheniramine | 23% |

Samples Containing Antihistamine Impurities



Synthetic Route Determination (4Q-2008)





Questions???

Contact Information:

Dr. Steven G. Toske Senior Research Chemist DEA Special Testing and Research Laboratory 22624 Dulles Summit Ct. Dulles, VA 20166 U.S.A. (703) 668-3332

Email: steven.g.toske@usdoj.gov